These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24859364)

  • 1. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
    Branford S; Yeung DT; Parker WT; Roberts ND; Purins L; Braley JA; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Donaldson Z; Leong M; Fletcher L; Seymour JF; Grigg AP; Ross DM; Hughes TP
    Blood; 2014 Jul; 124(4):511-8. PubMed ID: 24859364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
    Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
    Yeung DT; Osborn MP; White DL; Branford S; Braley J; Herschtal A; Kornhauser M; Issa S; Hiwase DK; Hertzberg M; Schwarer AP; Filshie R; Arthur CK; Kwan YL; Trotman J; Forsyth CJ; Taper J; Ross DM; Beresford J; Tam C; Mills AK; Grigg AP; Hughes TP;
    Blood; 2015 Feb; 125(6):915-23. PubMed ID: 25519749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
    Branford S; Kim DW; Soverini S; Haque A; Shou Y; Woodman RC; Kantarjian HM; Martinelli G; Radich JP; Saglio G; Hochhaus A; Hughes TP; Müller MC
    J Clin Oncol; 2012 Dec; 30(35):4323-9. PubMed ID: 23109697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
    Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.
    Millot F; Guilhot J; Baruchel A; Petit A; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Sirvent N; Yakouben K; Schmitt C; Gandemer V; Reguerre Y; Couillault G; Mechinaud F; Cayuela JM
    Blood; 2014 Oct; 124(15):2408-10. PubMed ID: 25170123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
    Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
    Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
    Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
    Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
    Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
    Hanfstein B; Shlyakhto V; Lauseker M; Hehlmann R; Saussele S; Dietz C; Erben P; Fabarius A; Proetel U; Schnittger S; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
    Leukemia; 2014 Oct; 28(10):1988-92. PubMed ID: 24798484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
    Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
    Stein AM; Martinelli G; Hughes TP; Müller MC; Beppu L; Gottardi E; Branford S; Soverini S; Woodman RC; Hochhaus A; Kim DW; Saglio G; Radich JP
    BMC Cancer; 2013 Apr; 13():173. PubMed ID: 23547655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
    Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
    Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
    Hughes TP; Hochhaus A; Branford S; Müller MC; Kaeda JS; Foroni L; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Rudoltz MS; Mone M; Wehrle E; Modur V; Goldman JM; Radich JP;
    Blood; 2010 Nov; 116(19):3758-65. PubMed ID: 20679528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.